Changes in Haemostasis and Inflammatory Markers after mRNA BNT162b2 and Vector Ad26.CoV2.S SARS-CoV-2 Vaccination
19 Pages Posted: 7 Feb 2023
Abstract
Introduction: Reported thromboembolic events after SARS-CoV-2 vaccinations are still raising concerns, predominantly in non-scientific population. The aim of our study was to investigate differences between haemostasis and inflammatory markers in subjects vaccinated with mRNA BNT162b2 and vector Ad26.CoV2.S vaccine.
Materials and methods: The study included 87 subjects vaccinated with mRNA BNT162b2 and 84 with Ad26.CoV2.S vaccine. All the laboratory parameters (TAT, F 1+2, IL-6, CRP, endothelin-1, platelets, fibrinogen, D-dimers, vWF activity) were investigated for mRNA vaccine at five (before the first dose, 7 and 14 days after the first and second vaccine dose), and three time points (before first dose, 7 and 14 days after) for vector vaccine, respectively. All markers were measured by well-established laboratory methods.
Results: Our results have shown statistically significant differences for TAT complexes levels between vaccines at three time points (P<0.001) and for CRP levels 7 days after vaccination (P=0.01). Furthermore, study has revealed statistically significant changes in D-dimers and vWF activity (P=0.004 and P<0.001) between tested time points in both subgroups.
Conclusion: Although statistically significant changes in haemostasis markers have been obtained, they remained clinically irrelevant. Thus, our study implicates that there is no plausible scientific evidence of significant disruption in the coagulation and inflammatory processes after vaccination with BNT162b2 mRNA and Ad26.CoV.S vector SARS-CoV-2 vaccines.
Note:
Funding Information: The study was performed as an integral part of the research project entitled „ The effect of BNT162b2 and Ad26.CoV2.S coronavirus vaccines on the parameters of hemostasis and inflammation “ that is approved and funded by the Foundation of Croatian cooperative group for hematologic diseases KROHEM.
Declaration of Interests: The authors state that they have no conflict of interest.
Ethics Approval Statement: The study was performed according to the guiding principles of the Declaration of Helsinki and was approved by the University Hospital Centre and Medical Centre’s Ethic committees. All subjects gave their informed written consent.
Keywords: COVID-19, vaccine, haemostasis, inflammation
Suggested Citation: Suggested Citation